Brief: Sciclone PharmaSays Nmpa Accepted BLA Of Danyelza (Naxitamab-Gqgk)
13/07/2021 02:36
July 13 (Reuters) - SciClone Pharmaceuticals (Holdings) Ltd
6600.HK :
* NMPA ACCEPTED BLA OF DANYELZA (NAXITAMAB-GQGK) FOR
TREATMENT OF
PATIENTS WITH RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA
Source text for Eikon: ID:nHKS7KsWlf
Further company coverage: 6600.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SciClone Pharmaceuticals (Holdings)
See all newsOneRobotics surges on plan to buy more shares
Brief: Onerobotics (Shenzhen) To Procure Affiliate Of Co To Acquire 59.9% Stake Of Nanoleaf Limited, Others
Brief: OneRobotics (Shenzhen) Says Final Offer Price Under Global Offering Is HK$73.80 Per H Share
Brief: Sciclone Pharmaceuticals (Holdings) Announces Proposal For Privatisation Of Co By Silver Pegasus Investment
Brief: SciClone Pharmaceuticals Says Trading In Shares Halted